IL13RA2 and central nervous system cancer: In glioma, expression of IL13Ra2 is distinct among gliomas with different molecular subtypes and WHO malignancy grade and positively correlates with tumor proliferation and invasion and immune evasion abilities, leading to poorer patient outcomes [18,21,22,23,24].